The strong early efficacy data is a positive catalyst, but the small sample and need for FDA review to complete enrollment warrant caution. Monitor for completion of the 10-patient pilot and any regulatory updates; the next major catalyst is the interim safety analysis and full enrollment milestone.
Price Chart
Executive Summary
Alpha Tau presented interim data from its REGAIN trial of Alpha DaRT for recurrent glioblastoma (GBM). Of the first three patients treated, two achieved complete responses and one stable disease with a 30% tumor reduction, with no unanticipated side effects. This is a strong early efficacy signal in a difficult-to-treat indication, though the sample is small and further enrollment and FDA review are pending.
Key Facts
- 3 patients treated in REGAIN trial for recurrent GBM
- 2 complete responses and 1 stable disease (30% size reduction) as of May 3, 2026
- No unanticipated side effects; grade 2-3 seizures occurred in 2 patients but resolved to baseline
- Plan to enroll 10 patients total pending FDA interim safety review
- Alpha DaRT uses diffusing alpha-emitters radiotherapy delivered via stereotactic implantation
Financial Impact
Pre-revenue company; no financial data provided
Risk Factors
- Small sample size (n=3) limits statistical reliability
- Two patients experienced grade 2-3 seizures, though manageable
- Regulatory and clinical risks: FDA may require additional data before allowing full enrollment
- Historical stock performance shows poor T+20 outcomes on prior news, but this is a distinct efficacy signal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-054252 |
| Document: ea0290058-6k_alpha.htm | 0001213900-26-054252 |
| Document: 0001213900-26-054252-index-headers.html | 0001213900-26-054252 |
| Document: 0001213900-26-054252-index.html | 0001213900-26-054252 |
| Document: 0001213900-26-054252.txt | 0001213900-26-054252 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 17w ago | 6-K | $1.02 $4.00 | ▲ +292.16% | ▲ +289.66% | — |
Jun 1, 2026 17w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +280.14% | — |
May 18, 2026 19w ago | 6-K | $1.02 $3.89 | ▲ +281.37% | ▲ +275.08% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 11, 2026 20w ago | 6-K | $1.02 $3.37 | ▲ +230.39% | ▲ +226.00% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 8, 2026 21w ago | 6-K | $1.02 $3.30 | ▲ +223.53% | ▲ +218.69% | — |
May 7, 2026 21w ago | 6-K | $1.02 $2.58 | ▲ +152.94% | ▲ +149.11% | — |
May 5, 2026 21w ago | 6-K | $1.02 $2.70 | ▲ +164.71% | ▲ +161.97% | — |
May 4, 2026 21w ago | 6-K | $1.02 $2.29 | ▲ +124.51% | ▲ +122.65% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access